Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Ewing sarcoma/PNET
Stage/Subtype:  recurrent Ewing sarcoma/PNET
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 52 for your search:
Start Over
Study in Localized and Disseminated Ewing Sarcoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 4 to 50
Sponsor: Other
Protocol IDs: 108128, EudraCT number: 2008-003658-13, NCT00987636
Post-operative Radiotherapy in Poor Responders Ewing's Sarcoma Patients
Phase: Phase III
Type: Treatment
Status: Active
Age: 1 to 18
Sponsor: Other
Protocol IDs: CCHE-BoneT002, NCT01734863
Reduced Intensity Transplant Using Extracorporeal Photopheresis
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: ECP RIT, NCT00179790
Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: BMT 0499 Solid, NCT00179816
Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AVF4761s, 200911736, NCT01106872
New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 3 to 75
Sponsor: Other
Protocol IDs: NDV-HUJ-HMO-CTIL, NCT01174537
Aerosol IL-2 for Pulmonary Metastases
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 12 and over
Sponsor: Other
Protocol IDs: 2010-0700, NCI-2012-00788, NCT01590069
Safety Study of CD3/CD19 Depleted Haploidentical Stem Cells
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 1 to 25
Sponsor: Other
Protocol IDs: 1075/01 PEI, NCT01919866
To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 6 months to 21 years
Sponsor: Pharmaceutical / Industry
Protocol IDs: ABI-007-PST-001, NCT01962103
BMN-673 and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 13 months to 30 years
Sponsor: NCI
Protocol IDs: NCI-2014-00804, ADVL1411, UM1CA097452, NCT02116777
Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 13 moths to 29 years
Sponsor: NCI, Other
Protocol IDs: 2013-171, NCI-2014-01149, P30CA022453, NCT02173093
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 12 months to 30 years
Sponsor: NCI
Protocol IDs: NCI-2014-01222, ADVL1412, UM1CA097452, NCT02304458
PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 3 to 30
Sponsor: NCI
Protocol IDs: 150093, 15-C-0093, NCT02390752
Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse
Phase: Phase II
Type: Treatment
Status: Active
Age: 1 to 25
Sponsor: Other
Protocol IDs: NAVE-CYCLO, NCT00180947
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: 05-122, MSKCC-05122, NCT00445965
Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas
Phase: Phase II
Type: Treatment
Status: Active
Age: 30 and under
Sponsor: NCI, Other
Protocol IDs: 05-326, Other, NCT00592293
Activated Allogeneic Lymphocytes for Induction Graft Versus Tumor Effect in Metastatic Solid Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 12 to 70
Sponsor: Other
Protocol IDs: 0457-08-HMO-CTIL, NCT00855452
Gemcitabine,Vincristine and Cisplatin as Second Line Combination Therapy in Patients With Sarcoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: GVP-SAR, NCT01192633
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: NCI
Protocol IDs: NCI-2011-02605, CDR0000686608, COG-ACNS0821, ACNS0821, U10CA180886, U10CA098543, NCT01217437
Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas.
Phase: Phase II
Type: Diagnostic, Treatment
Status: Active
Age: 5 to 49
Sponsor: Other
Protocol IDs: NCCCTS-08-322, NCT01380275
Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 0 to 21
Sponsor: Other
Protocol IDs: 11-183, NCT01492673
Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults
Phase: Phase II
Type: Treatment
Status: Active
Age: 40 and under
Sponsor: Other
Protocol IDs: GEIS-21, 2009-016027-62, NCT01696669
A Phase II Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 0 to 40
Sponsor: Other
Protocol IDs: J12106, NCT01804634
Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 21
Sponsor: Other
Protocol IDs: CR0113061, NCT01807468
Start Over